376 related articles for article (PubMed ID: 28003306)
21. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
23. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
24. MYCN regulates oncogenic MicroRNAs in neuroblastoma.
Schulte JH; Horn S; Otto T; Samans B; Heukamp LC; Eilers UC; Krause M; Astrahantseff K; Klein-Hitpass L; Buettner R; Schramm A; Christiansen H; Eilers M; Eggert A; Berwanger B
Int J Cancer; 2008 Feb; 122(3):699-704. PubMed ID: 17943719
[TBL] [Abstract][Full Text] [Related]
25. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.
Chen Y; Stallings RL
Cancer Res; 2007 Feb; 67(3):976-83. PubMed ID: 17283129
[TBL] [Abstract][Full Text] [Related]
26. MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.
Beckers A; Van Peer G; Carter DR; Gartlgruber M; Herrmann C; Agarwal S; Helsmoortel HH; Althoff K; Molenaar JJ; Cheung BB; Schulte JH; Benoit Y; Shohet JM; Westermann F; Marshall GM; Vandesompele J; De Preter K; Speleman F
Cancer Lett; 2015 Sep; 366(1):123-32. PubMed ID: 26123663
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
[TBL] [Abstract][Full Text] [Related]
28. Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity.
Alptekin A; Ye B; Yu Y; Poole CJ; van Riggelen J; Zha Y; Ding HF
Oncogene; 2019 Dec; 38(50):7504-7520. PubMed ID: 31444411
[TBL] [Abstract][Full Text] [Related]
29. MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer.
Zheng G; Li N; Jia X; Peng C; Luo L; Deng Y; Yin J; Song Y; Liu H; Lu M; Zhang Z; Gu Y; He Z
J Mol Med (Berl); 2016 Oct; 94(10):1129-1141. PubMed ID: 27055844
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
[No Abstract] [Full Text] [Related]
31. ALK positively regulates MYCN activity through repression of HBP1 expression.
Claeys S; Denecker G; Durinck K; Decaesteker B; Mus LM; Loontiens S; Vanhauwaert S; Althoff K; Wigerup C; Bexell D; Dolman E; Henrich KO; Wehrmann L; Westerhout EM; Demoulin JB; Kumps C; Van Maerken T; Laureys G; Van Neste C; De Wilde B; De Wever O; Westermann F; Versteeg R; Molenaar JJ; Påhlman S; Schulte JH; De Preter K; Speleman F
Oncogene; 2019 Apr; 38(15):2690-2705. PubMed ID: 30538293
[TBL] [Abstract][Full Text] [Related]
32.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
33. MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression.
Liu Y; Liu D; Wan W
Biochem Biophys Res Commun; 2019 Mar; 511(1):35-40. PubMed ID: 30765227
[TBL] [Abstract][Full Text] [Related]
34. Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.
Samaraweera L; Spengler BA; Ross RA
Oncol Rep; 2017 Jul; 38(1):545-550. PubMed ID: 28560387
[TBL] [Abstract][Full Text] [Related]
35. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma.
Megiorni F; Colaiacovo M; Cialfi S; McDowell HP; Guffanti A; Camero S; Felsani A; Losty PD; Pizer B; Shukla R; Cappelli C; Ferrara E; Pizzuti A; Moles A; Dominici C
Oncol Rep; 2017 Jul; 38(1):3-20. PubMed ID: 28586032
[TBL] [Abstract][Full Text] [Related]
36. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
37. Direct Targeting of
Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
[TBL] [Abstract][Full Text] [Related]
38. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
[TBL] [Abstract][Full Text] [Related]
39. microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.
Zhao Z; Ma X; Sung D; Li M; Kosti A; Lin G; Chen Y; Pertsemlidis A; Hsiao TH; Du L
RNA Biol; 2015; 12(5):538-54. PubMed ID: 25760387
[TBL] [Abstract][Full Text] [Related]
40. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]